COVID-19 Vaccine: Booster Dose Guidance for Adolescents (pdf, February 4, 2022)

COVID-19 Vaccine: Clarifying Recommended and Minimum Intervals (pdf, January 12, 2022)

COVID-19 Vaccine: Moderna for individuals aged ≥ 30 years (pdf, December 31, 2021)

COVID-19 Vaccine: updated third/booster dose interval for individuals aged ≥ 50 years and updated vaccine product for individuals aged ≥ 30 years (pdf, December 24, 2021)

COVID-19 Vaccine: updated third/booster dose guidance and preferential use of Pfizer/Comirnaty^TM for 12 to 29 year olds (pdf, December 10, 2021)

COVID-19 Vaccine: Approval/Guidance for Children aged five to ≤ 11 years (pdf, November 23, 2021)

COVID-19 Vaccine Update: Pharmacists to Start Administering COVID-19 and Influenza Vaccines to Those Five Years of Age and Older (pdf, November 16, 2021)

COVID-19 Vaccine Update: Expanded Third/ Booster Dose 6 Months After Dose 2 Guidance (pdf, November 10, 2021)

COVID-19 Vaccine: Third/Booster Dose Update (pdf, November 5, 2021)

COVID-19 Vaccine RE: Important Program Updates (pdf, November 3, 2021)

Moderna/Spikevax - Shelf life extension for US Labeled 14 dose vials (pdf, October 29, 2021)

COVID-19 Vaccine: Booster/Third Dose Guidance and Expansion to Include Residents of Congregate Elderly Person Housing Sites (pdf, October 27, 2021)

COVID-19 Vaccine Medical Exemption Program (pdf, October 6, 2021)

COVID-19 Vaccine: Expansion of Third Doses to Health Care Personnel and to People who received a Viral Vector Vaccine Series (pdf, October 5, 2021)

Manitoba Adopting National Advisory Committee on Immunization (NACI) Guidance (pdf, October 1, 2021)

COVID-19 Vaccine Guidance for Personal Care Homes: Recommended Interval between Second and Third Doses of COVID-19 Vaccine & Update on COVID-19/Flu Vaccine Sequence of Administration (pdf, September 23, 2021)

COVID-19 Vaccine: Expansion of Third Doses to Personal Care Homes (pdf, September 20, 2021)

COVID-19 Vaccine: Additional Information on Third Doses (pdf, September 17, 2021)

COVID-19 Vaccine: Additional mRNA Vaccine Dose for Certain Populations and Medical Exemption Program (pdf, September 15, 2021)

Reporting COVID-19 and School Vaccine Doses Administered to Clients without a PHIN (pdf, September 2021)

Pfizer - Shelf life extension for identified lots in Ultra Low Temperature Storage (pdf, August 30, 2021)

COVID-19 Vaccine: Recommendations for Immunizing Adolescents (pdf, August 2021)

COVID-19 Vaccine: Updated Age Eligibility Criteria for Children (pdf, August 2021)

COVID-19 Vaccine: UPDATE - Allergy Assessment and Referral Update (pdf, July 2021)

COVID-19 Vaccine: Allergy Assessment and Referral (pdf, June 2021)

Employee Under Investigation and Case Summary Template (EUICS) Guideline (pdf, May 2021)

Employee Under Investigation and Case Summary Template (EUICS) Guideline (xlsx, May 2021)

IMPORTANT NOTICE: Effective immediately, pause use of AstraZeneca / COVISHIELD in People aged < 55 years (pdf, March 29, 2021)

First Nations Identification for the Purpose of Booking AstraZeneca/ Covishield Vaccination (pdf, March 29, 2021)

Manitoba COVID-19 Vaccine: Updated AstraZeneca and COVISHIELD Product Monographs and Health Product Risk Communication (pdf, March 25, 2021)

Health Product Risk Communication: Important Safety Information on AstraZeneca and COVISHIELD Vaccines (pdf, March 24, 2021)

COVID-19 Vaccine: New/Updated Communications Products including Clinical Practice Guidelines and Consent Form (pdf, March 15, 2021)

COVID-19 Vaccine: Guidance for Immunizers to Select the Reason for Immunization (pdf, March 2, 2021)

Memo to Health Care Providers on Enhanced Consent (pdf, January 25, 2021)

Pfizer BioNTech - Information for health care providers (manufacturer site)

CanVax: COVID-19 Vaccine Questions and Answers for Healthcare Providers

Memo to Health Care Providers (pdf, December 15, 2020)